Alpha Teknova (NASDAQ:TKNO – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
Valuation & Earnings
This table compares Alpha Teknova and Azenta”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $45.95 million | 10.77 | -$17.26 million | ($0.29) | -27.14 |
| Azenta | $621.70 million | 3.31 | -$166.99 million | ($3.62) | -12.97 |
Alpha Teknova has higher earnings, but lower revenue than Azenta. Alpha Teknova is trading at a lower price-to-earnings ratio than Azenta, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by company insiders. Comparatively, 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Alpha Teknova and Azenta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -34.76% | -24.95% | -16.27% |
| Azenta | -26.86% | 1.41% | 1.15% |
Risk & Volatility
Alpha Teknova has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Alpha Teknova and Azenta, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 1 | 1 | 4 | 0 | 2.50 |
| Azenta | 1 | 2 | 4 | 0 | 2.43 |
Alpha Teknova currently has a consensus price target of $8.75, indicating a potential upside of 11.18%. Azenta has a consensus price target of $47.60, indicating a potential upside of 1.40%. Given Alpha Teknova’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Teknova is more favorable than Azenta.
Summary
Azenta beats Alpha Teknova on 7 of the 13 factors compared between the two stocks.
About Alpha Teknova
Alpha Teknova, Inc. develops and manufactures reagents used in life science research and the development and production of biopharmaceuticals and diagnostic products. Its offerings include cell culture media, buffers, molecular biology reagents, proteins and other laboratory materials. The company provides both catalog products and custom reagent development and manufacturing services. Its customers include biotechnology and pharmaceutical companies, diagnostic developers, academic institutions and research laboratories.
About Azenta
Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
